ARTICLE | Company News
Albany Molecular Research, Bristol-Myers deal
October 31, 2005 8:00 AM UTC
AMRI granted BMY an exclusive license to develop and commercialize undisclosed amine neurotransmitter reuptake inhibitors to treat depression and other CNS disorders. AMRI will receive $8 million up f...